NCT01765972

Brief Summary

The primary purpose of this clinical trial is to evaluate the eye's response to three test soft contact lenses as well as no lens wear, with respect to Corneal Staining.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2012

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2012

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 8, 2013

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 11, 2013

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2013

Completed
3.2 years until next milestone

Results Posted

Study results publicly available

July 20, 2016

Completed
Last Updated

June 19, 2018

Status Verified

July 1, 2016

Enrollment Period

5 months

First QC Date

January 8, 2013

Results QC Date

June 10, 2016

Last Update Submit

June 18, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage Change From Baseline of Corneal Swelling 8 Hours Post Fit

    Central corneal thickness was measured at baseline and 8-hour post fit with a modified optical pachometer on a Zeiss biomicroscope, interfaced to a PC. The pachometry measurement included seven readings; the computer is programmed to remove the high and low readings and to calculate the average of the remaining five readings. Only a single central corneal thickness measurement, the average of the 5 readings, was recorded by the investigator in the eCRF. The average percent change from baseline of corneal swelling was reported and was calculated as: ((Post fit - Baseline)/ Baseline) X 100.

    8 hours post fit

Study Arms (4)

Test 1/Spectacles/Test 2/Test 3

OTHER

Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 1 (etafilcon A with Lacreon), spectacles, TEST 2 (etafilcon A with Lacreon with print) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.

Device: etafilcon A with LacreonDevice: etafilcon A with Lacreon with printDevice: etafilcon A with printDevice: Spectacles (habitual)

Test 2/Test 3/ Spectacles/Test 1

OTHER

Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 2 (etafilcon A with Lacreon with print), TEST 3 (etafilcon A with print), spectacles and TEST 1 (etafilcon A with Lacreon) in both eyes for 8 +/-1 hours.

Device: etafilcon A with LacreonDevice: etafilcon A with Lacreon with printDevice: etafilcon A with printDevice: Spectacles (habitual)

Test 3/Test 1/ Test 2/ Spectacles

OTHER

Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 3 (etafilcon A with print), TEST 1 (etafilcon A with Lacreon), TEST 2 (etafilcon A with Lacreon with print) and spectacles in both eyes for 8 +/-1 hours.

Device: etafilcon A with LacreonDevice: etafilcon A with Lacreon with printDevice: etafilcon A with printDevice: Spectacles (habitual)

Spectacles/Test 2/Test 1/Test 3

OTHER

Subjects assigned randomly to this arm will wear the study lenses sequentially as spectacles, TEST 2 (etafilcon A with Lacreon with print), TEST 1 (etafilcon A with Lacreon) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.

Device: etafilcon A with LacreonDevice: etafilcon A with Lacreon with printDevice: etafilcon A with printDevice: Spectacles (habitual)

Interventions

contact lens with Lacreon

Also known as: Test 1
Spectacles/Test 2/Test 1/Test 3Test 1/Spectacles/Test 2/Test 3Test 2/Test 3/ Spectacles/Test 1Test 3/Test 1/ Test 2/ Spectacles

contact lens with Lacreon and cosmetic print

Also known as: Test 2
Spectacles/Test 2/Test 1/Test 3Test 1/Spectacles/Test 2/Test 3Test 2/Test 3/ Spectacles/Test 1Test 3/Test 1/ Test 2/ Spectacles

contact lens with print

Also known as: Test 3
Spectacles/Test 2/Test 1/Test 3Test 1/Spectacles/Test 2/Test 3Test 2/Test 3/ Spectacles/Test 1Test 3/Test 1/ Test 2/ Spectacles

Spectacles

Spectacles/Test 2/Test 1/Test 3Test 1/Spectacles/Test 2/Test 3Test 2/Test 3/ Spectacles/Test 1Test 3/Test 1/ Test 2/ Spectacles

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  • The subject must appear able and willing to adhere to the instructions set forth in the clinical protocol.
  • The subject must be between 18 and 45 years of age.
  • The subject must be an adapted soft contact lens wearer in both eyes.
  • The subject must be of East or Southeast Asian descent, e.g. ethnic Chinese, Japanese, Korean, Malay, Vietnamese, Indonesian, Filipino, etc. (it is preferred but not required that both the subject's biological parents are East or Southeast Asian ethnicity, by self report).
  • The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 D in each eye.
  • The subject's refractive cylinder must be no more than 1.00D in each eye.
  • The subject must have best corrected visual acuity of +0.14 logMAR (equivalent to 20/25-2) or better in each eye.
  • Subjects must own a wearable pair of spectacles and wear them on the day of the initial visit, during the washout before each phase and during the no lens wear phase.
  • The subject must have normal eyes (i.e., no ocular medications or infections of any type).

You may not qualify if:

  • Are currently pregnant or lactating by self report (subjects who become pregnant during the study will be discontinued).
  • Have any ocular or systemic allergies or diseases that may interfere with contact lens wear.
  • Have any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but may not be limited to, diabetes. hyperthyroidism, recurrent herpes simplex/zoster, Sjogren's syndromes, xerophthalmia, acne rosacea, Stevens-Johnson syndromes, HIV/AIDS, hepatitis, and tuberculosis.
  • Use of any topical medications such aas eye drops or ointments.
  • Have entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosion, or aphakia.
  • Had any previous, or planned ocular or intraocular surgery (e.g. cataract surgery, radial keratotomy, PRK, LASIK, etc.).
  • Have any grade 2.0 or greater slit lamp findings (e.g. edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the Efron classification scale or any other ocular abnormality that may contraindicate contact lens wear.
  • Have any known hypersensitivity or allergic reaction to one of the study products.
  • Have any ocular infection.
  • Have any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  • Have participated in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
  • Have any infectious disease (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV by self report).
  • Currently wear their contact lenses on an extended wear basis.
  • Are an employee of the investigational clinic (e.g. Investigator, Coordinator, Technician)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unknown Facility

Waterloo, Ontario, Canada

Location

MeSH Terms

Interventions

Eyeglasses

Intervention Hierarchy (Ancestors)

LensesOptical DevicesEquipment and Supplies

Results Point of Contact

Title
Katherine Osborn Lorenz, OD, MS
Organization
Johnson & Johnson Vision Care Inc.

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
GT60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 8, 2013

First Posted

January 11, 2013

Study Start

December 1, 2012

Primary Completion

May 1, 2013

Study Completion

May 1, 2013

Last Updated

June 19, 2018

Results First Posted

July 20, 2016

Record last verified: 2016-07

Locations